Analyst Reco. IGM Biosciences, Inc.

Equities

IGMS

US4495851085

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
9.4 ^USD	+22.88%		+30.56%	+13.12%

Apr. 17	IGM Biosciences, Sanofi Narrow Partnership to Focus on Potential Immunology and Inflamation Targets	MT
Apr. 17	IGM Biosciences, Inc. Announces Refocusing of Sanofi Collaboration	CI

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

HC Wainwright Adjusts IGM Biosciences Price Target to $12 From $7, Maintains Neutral Rating	Mar. 12	MT
RBC Upgrades IGM Biosciences to Outperform From Sector Perform, Boosts Price Target to $21 From $9; Speculative Risk Kept	Feb. 09	MT
BofA Securities Downgrades IGM Biosciences to Neutral From Buy, Adjusts Price Target to $8 From $20	Dec. 15	MT
HC Wainwright Downgrades IGM Biosciences to Neutral From Buy, Cuts Price Target to $7 From $11	Dec. 07	MT
Wedbush Raises IGM Biosciences' PT to $20 From $16, Adjusts Downstream Funding Assumptions; Keeps Outperform Rating	Dec. 06	MT
RBC Raises Price Target on IGM Biosciences to $9 From $8 on Reduced Ancillary Spend Amid Job Cuts, Keeps Sector Perform, Speculative Risk	Dec. 06	MT
Morgan Stanley Adjusts IGM Biosciences Price Target to $8 From $15, Maintains Equal Weight Rating	Nov. 15	MT
HC Wainwright Adjusts Price Target on IGM Biosciences to $11 From $17, Keeps Buy Rating	Nov. 15	MT
Stifel Trims IGM Biosciences' Price Target to $25 From $26, Keeps Buy Rating	Nov. 14	MT
RBC Cuts Price Target on IGM Biosciences to $8 From $11, Keeps Sector Perform, Speculative Risk	Nov. 14	MT
Wedbush Lowers IGM Biosciences' Price Target to $16 From $19, Keeps Outperform Rating	Nov. 14	MT
HC Wainwright Adjusts IGM Biosciences' Price Target to $17 From $22, Keeps Buy Rating	23-08-07	MT
Morgan Stanley Adjusts Price Target on IGM Biosciences to $15 From $20, Maintains Equal-Weight Rating	23-08-07	MT
RBC Cuts Price Target on IGM Biosciences to $11 From $17, Maintains Sector Perform Rating, Speculative Risk Qualifier	23-08-07	MT
Wedbush Cuts IGM Biosciences' PT to $19 From $37, Notes Focus of Aplitabart in mCRC, Removes Potential Imvotamab Oncology Revenues; Keeps Outperform Rating	23-08-04	MT
JPMorgan Adjusts Price Target on IGM Biosciences to $19 From $26, Maintains Neutral Rating	23-05-16	MT
RBC Cuts Price Target on IGM Biosciences to $17 From $21, Maintains Sector Perform, Speculative Risk	23-05-15	MT
Wedbush Lowers IGM Biosciences' Price Target to $37 From $41, Adjusts Future Financing Assumptions; Keeps Outperform Rating	23-05-15	MT
Truist Securities Lowers Price Target on IGM Biosciences to $25 From $37, Maintains Buy Rating	23-04-04	MT
JPMorgan Chase Adjusts Price Target on IGM Biosciences to $26 From $27, Maintains Neutral Rating	23-04-03	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. IGM Biosciences, Inc.

Equities

IGMS

US4495851085

Analyst Reco.

Filters